Shares of health-care companies fell amid doubts about the regulatory outlook.
The second push this year to pass a bill replacing the Affordable Care Act appears to have slowed amid criticism of the new bill's provisions.
Continue Reading Below
Biotech indexes are outperforming the broad market for the year to date, a trend that historically has led to growing momentum in the balance of the year, said analysts at J.P. Morgan.
-By Rob Curran, email@example.com
(END) Dow Jones Newswires
May 26, 2017 18:22 ET (22:22 GMT)